Partnership between small biotech and big pharma

IDrugs

Volumn 9, Issue 8, 2006, Pages 560-564

  Wiederrecht, Gregory J ^b   Hill, Raymond G ^a   Beer, Margaret S ^a  

^a Merck Sharp & Dohme Limited   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Big pharma; Biotech; Democratization; Innovation; Partnering

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; ANTIDIABETIC AGENT; ANTIVIRUS AGENT; ARUNDIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; AURORA B KINASE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; ETORICOXIB; GABOXADOL; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LURASIDONE; MK 0518; MK 0646; MONOCLONAL ANTIBODY; NGD 8243; NMED 160; PHOSPHOTRANSFERASE INHIBITOR; PROTON PUMP INHIBITOR; ROTAVIRUS VACCINE; SEROTONIN UPTAKE INHIBITOR; SITAGLIPTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VARICELLA ZOSTER VACCINE; VORINOSTAT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVISORY COMMITTEE; ARTHRITIS; ARTICLE; BIOINFORMATICS; BIOMEDICAL TECHNOLOGY ASSESSMENT; BIOTECHNOLOGY; CANCER; CLINICAL TRIAL; CRYSTALLOGRAPHY; DEPRESSION; DIABETES MELLITUS; DNA MICROARRAY; DRUG DESIGN; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; FUNDING; GASTROINTESTINAL DISEASE; HEART DISEASE; HERPES ZOSTER; HIGH THROUGHPUT SCREENING; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; LICENSING; LIFE EXPECTANCY; LIFESTYLE; MEDICAL RESEARCH; MENTAL DISEASE; MICROFLUIDICS; OSTEOPOROSIS; PAIN; PROFESSIONAL PRACTICE; PROTEOMICS; PUBLIC HEALTH; VACCINATION; VIRAL GASTROENTERITIS;

BIOTECHNOLOGY; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS;

EID: 33747615982     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Zambrowicz BP, Sands AT: Knockouts model the 100 best selling drugs - will they model the next 100? Nat Rev Drug Discov (2003) 2(1):38-51.
2. Greene J, Carey J, Arndt M, Port O: Re-inventing corporate R&D. Businessweek (2003): September.
3. Sharma D: Biotech Hubs - key growth engines for drug discovery. Decision Resources (2004).
4. Brown P: Investing in the future of R&D. Scrip Mag (2003):3-4.
5. Koppal K: Finding new drugs through alliances. Drug Disc Dev (2003):22-28.
6. Lee E: Rethinking strategy to drive R&D performance. FT Global Pharmaceutical Conference, London, UK (October, 21 2003).
7. Kalamas J, Pinkus G: The optimum time for drug licensing. Nat Rev Drug Discov (2003) 2(9):691-692.
8. Senior M: Roche's partners: Replacing or fuelling in-house R&D? In Vivo Europe (2003) 2:2-5.
9. Futrel D, Slugay M, Stephens CH: Becoming a premier partner: Measuring, managing and changing partnering capabilities at Eli Lilly and Company. J Commercial Biotechnol (2001) 8:5-13.
10. Bayer focuses internally: In-licensing, in-house R&D are priorities. The Pink Sheet (2003) 65(046):30-32.
11. GSK decreases reliance on late-stage licenses, citing strength In R&D. The Pink Sheet (2003) 65(049):9-10.
12. Trudinger M: Attracting big pharma. Biotech News Australia (2003):8-9.